ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing therapies for inflammatory and renal diseases. Its business centers on drug candidates and related intellectual property rather than commercialized products, with operations organized around research, development, and clinical-stage advancement.

0.03

— ZyVersa Therapeutics, Inc.
	%
Inflammatory disease therapeutics	50% Drug candidates and development programs targeting inflammatory pathways and related disorders.
Renal disease therapeutics	30% Research and development programs focused on kidney and renal-related diseases.
Intellectual property and pipeline assets	20% Patents, formulations, and other proprietary assets supporting the development pipeline.

ZyVersa does not appear to sell commercial products to end customers in the traditional sense; its economic...

Capital providersprimary
Equity investors and financing counterparties that fund the company’s development programs and corporate operations.
Research collaboratorssecondary
Scientific and development partners that may support preclinical or clinical work on pipeline assets.
Future healthcare customersemerging
Hospitals, physicians, specialty pharmacies, and payers that would buy approved therapies if programs succeed.

ZyVersa is headquartered in the United States and its business is organized from a U.S. corporate base...

•Headquartered in the United States
•Primary exposure is to U.S. capital markets and regulation
•Clinical and research work may rely on external partners
•No country-level revenue disclosure was provided

The company’s strategic focus is to advance its therapeutic pipeline through research, development, and clinical...

Advance pipeline candidatesshort-term

Clinical and regulatory progress is the main driver of value in a development-stage biotech model.

Secure financingshort-term

Biopharmaceutical development requires ongoing capital before product revenue exists.

Preserve intellectual propertymedium-term

Patent and proprietary asset protection supports partnering leverage and future commercialization.

ZyVersa faces the typical risks of a development-stage biotech company: clinical failure, regulatory delay, and...

critical

Clinical development failure

Drug candidates may not meet endpoints or safety requirements, which can eliminate pipeline value.

Scope: Inflammatory and renal disease programs
Materiality: high

high

Financing and dilution risk

The company relies on external capital to fund R&D before commercial revenues exist.

Scope: Equity issuance and related financing arrangements
Materiality: high

high

Nasdaq delisting and OTC trading risk

Reduced exchange access can lower liquidity, widen spreads, and impair investor demand.

Scope: Common stock trading on OTCQB
Materiality: high

medium

Penny stock classification

Broker-dealer suitability and sales practice rules can restrict trading and marketability.

Scope: Public market trading in common stock
Materiality: medium

low

Regulatory and tax changes

Changes in laws or operations can affect compliance burden and effective tax rate.

Scope: U.S. corporate and tax environment
Materiality: low

Equity financing and warrant accounting

Can create non-cash gains/losses and affect dilution

Stock-based compensation

Affects reported operating loss and share count

Fair value measurements

Can introduce earnings volatility

Going concern assessment

May influence disclosure and investor perception

ZyVersa Therapeutics, Inc.

Clinical development failure

Financing and dilution risk

Nasdaq delisting and OTC trading risk

Penny stock classification

Regulatory and tax changes

Zai Lab Ltd

VERTEX PHARMACEUTICALS INC / MA

UNITED THERAPEUTICS Corp

Zymeworks Inc.

ZEVRA THERAPEUTICS, INC.

Xeris Biopharma Holdings, Inc.